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Purpose/Objective: The goal of this work is to study TNRD 
(Thermal Neutron Rate Detector) response in high and low 
energies of clinical environments, to reject the photon 
component in peripheral dose measurements where mixed 
gamma and neutron fields are present. 
Materials and Methods: Four TNRD detectors [1] and a 
Farmer PTW ionization chamber were simultaneously used to 
obtain neutron and photon doses. Measurements were 
performed in a Siemens Primus linac with 6 and 15 MV photon 
beams (300MU/min) using a 40x10 cm2 field. One minute 
irradiation times were used with both detectors placed in the 
middle of an 8 cm methacrylate block under out-of-field 
geometries (see figure). The study was carried out for 9 
different field edge-detector distances, which meant photon 
dose rates ranging from 0.16 to 6 cGy/min.  
 
Figure. 
 
 
Results: As expected, for each location, similar readings from 
the IC were obtained for both energies as an indication of the 
low dependence of photon peripheral doses with the energy 
[2]. An average difference of 0.26 cGy (photon dose) for IC 
readings in both energies, except for 5 cm to the field edge 
(not relevant for peripheral doses) was obtained. Neutron 
presence in 6 MV was evaluated with the SRAMnd [4] (Static 
Random Access Memory neutron detector), with a negligible 
neutron presence (~1%). These two results allowed, from the 
subtraction of the 6MV and the 15MV readings, the neutron 
component discrimination for each measured situation (see 
table with averaged values).Photon presence (6 MV) increases 
when getting closer to the field edge, which is predicted by 
the IC in accordance with TNRD readings. If we would 
establish a limit to trust TNRD neutron measurement, a noise 
(photon) lower than 10% of the signal (neutron) could be 
considered acceptable. This value is obtained 30 cm far from 
the field edge, corresponding to a photon dose around 0.5 
cGy.  
 
Table. TNRD readings for 6 and 15 MV measurements and 
neutron component (substraction of both readings), for the 9 
studied distances.  
 
Conclusions: A photon rejection uncertainty has been 
estimated for TNRD detectors under some clinical special 
conditions. Although patient measurements are perfectly 
feasible with this type of detector [3] due to the low photon 
contribution when using the methodology established for 
model generation [4], photon contribution limit should be 
studied for new detectors. Nevertheless, as we can assume 
that photon components are close for both energies, being 15 
MV one at least as that of 6 MV, a good approximation to 
obtain more precise neutron doses, would be the subtraction 
of signals (corresponding to measurements at 6 and 15 MV 
under the same conditions), as shown in the table. This 
would allow having reliable neutron measurements much 
closer than 30 cm to the field-edge (e.g. 10-15 cm). 
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Purpose/Objective: To assess the radiation dose to the fetus 
of a pregnant patient undergoing high-dose-rate (HDR) 192Ir 
interstitial breast brachytherapy, and to design a new patient 
setup and lead shielding technique that minimizes the fetal 
dose. 
Materials and Methods: The pregnant woman was planned to 
be seated in a chair with the breast over a table and inside a 
leaded box specifically designed to protect the fetus. A total 
of 36 Gy in 8 fractions were prescribed. The shielding design 
is shown in the Figure. It consisted of a 3.5 cm thick layer of 
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lead placed between the breast and the table. Thus, during 
the treatment, the breast rested over this lead shield. In 
addition, two lateral pieces of lead (3 cm thick each) were 
added. One of the lateral layers had a port through which the 
transfer tubes were connected to the catheters. The lateral 
blocks allowed placing an extra piece of lead (2.5 cm thick) 
above the breast, parallel to the first layer, aiming to reduce 
primary radiation to the thyroids and eye lenses. In addition, 
in order to minimize the transit dose when the 192Ir source 
exits and returns to the remote afterloader, a hollow lead 
tube was made, which covered the transfer tubes. Finally, a 
layer of water-equivalent material (1 mm thick) was placed 
between the lead shielding and the patient skin to minimize 
the backscattering and electron contamination coming from 
the shield. Radiochromic films and thermoluminescent 
dosimeters were placed between the slices of an 
anthropomorphic phantom modeling the patient. Dose 
variation as a function of distance from the implant volume 
as well as dose homogeneity within a representative slice of 
the fetal position was evaluated without and with shielding. 
 
 
Results: When using the shielding, the peripheral dose 
decreased exponentially with the distance, and ranged from 
50 cGy at 5 cm from the caudal edge of the breast to < 0.1 
cGy at 30 cm. The shielding reduces absorbed dose by a 
factor of two near the breast and more than an order of 
magnitude beyond 20 cm. The dose is heterogeneous within a 
given patient axial plane, with measured variations from the 
central region within 50%. The fetal dose evaluated in this 
study with the designed lead shielding was compared with 
reported doses to the fetus from external-beam radiotherapy 
(EBRT) applied to the breast. Interstitial HDR 192Ir 
brachytherapy with breast shielding can be more 
advantageous than EBRT from a radiation protection point of 
view for pregnant patients, as long as the distance to the 
fundus is higher than 10 to 12 cm. Furthermore, the weight 
of the shielding here proposed (roughly 40 kg) is notably 
lower than the ones needed in EBRT (around 200 kg). 
Conclusions: Shielded HDR breast brachytherapy is a 
treatment option that may benefit pregnant patients needing 
localized radiotherapy, especially during the early gestational 
ages when the fetus is more sensitive to ionizing radiation.  
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Purpose/Objective: The purpose was to estimate the dose to 
the foetus in a case when a pregnant patient, 16 weeks after 
conception, were in need of stereotactic radiotherapy with 
6MV against head and lung. 
Materials and Methods: Four treatment plans, three for the 
brain metastasis and one for the lung metastasis, were 
available. The prescribed doses were 25 Gy x 1 fraction for 
the brain tumours and 15 Gy x 3 fractions for the lung. The 
photon energy spectrum in the position of foetus (about 32cm 
from lower field limit in the lung treatment) and the 
normalised dose (µGy/MU) in certain distances from the 
treatment volume were available from literature 1. Four 
different approaches for dose estimates were used: 1) based 
on measurements with ionisation chamber in an Alderson full 
body phantom, 2) tps data estimated from the scanned 
Alderson full body phantom (Oncentra v.4.3, Elekta), 3) 
measurements with TLD at the skin entrance during patient 
treatment and 4) based on literature. 
Results: In table 1 are the different plans and measurements 
with ionisation chamber summarized. The measurements in 
Alderson were in total 40mGy, 34 mGy from the plan in the 
lung and the remaining from the brain-plans. The tps 
calculated the dose in Alderson from the lung-plan to 53mGy. 
TLD measurements showed 30mGy (no energy correction) and 
from literature the estimated dose became 60mGy (4x4cm2 
fields). In total the foetus dose was estimated to 40±10 mGy. 
 
 
